July 18, 2023 03:02 PM EDT
Pharma
FDA+
Manufacturing

Man­u­fac­tur­ers, in­dus­try groups com­ment on FDA’s con­trol over ni­trosamines in drug prod­ucts

Tyler Patchen

News Reporter

The FDA has re­ceived com­ments from man­u­fac­tur­ers and oth­er in­dus­try play­ers on how best to tack­le im­pu­ri­ties known as ni­trosamines in drugs.

In May, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times